A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA: a Cancer Journal for Clinicians 2012;62:10-29
   PubMed Web of Science ®Google Scholar
• Rakha EA, El-Sayed ME, Lee AH, et al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol 2008;26:3153-8
   PubMed Web of Science ®Google Scholar
• DiPippo AJ, Patel NK, Barnett CM. Cyclin-dependent kinase inhibitors for the treatment of breast cancer: past, present, and future. Pharmacotherapy 2016;36:652-67
   PubMed Web of Science ®Google Scholar
• Austreid E, Lonning PE, Eikesdal HP. The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy. Expert Opin Pharmacother 2014;15:681-700
   PubMed Web of Science ®Google Scholar
• Sendur MA, Zengin N, Aksoy S, Altundag K. Everolimus: a new hope for patients with breast cancer. Curr Med Res Opin 2014;30:75-87
   PubMed Web of Science ®Google Scholar
• FDA approval of palbociclib and letrozole for first line treatment in postmenopausal women with HR-positive, HER2-negative advanced breast cancer. Available at: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm432886.htm. May 2017
   Google Scholar
• FDA approval palbociclib and fulvestrant in women with HR-positive, HER2-negative metastatic breast cancer. Available at: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm487080.htm. may 2017
   Google Scholar
• Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nature Rev Canc 2009;9:153-66
   PubMed Web of Science ®Google Scholar
• Bertoli C, Skotheim JM, de Bruin RA. Control of cell cycle transcription during G1 and S phases. Nat Rev Mol Cell Biol 2013;14:518-28
   PubMed Web of Science ®Google Scholar
• Finn RS, Aleshin A, Slamon DJ. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. Breast Canc Res 2016;18:17
   PubMed Web of Science ®Google Scholar
• Gampenrieder SP, Rinnerthaler G, Greil R. CDK4/6 inhibition in luminal breast cancer. Memo 2016;9:76-81
   PubMedGoogle Scholar
• Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81:323-30
   PubMed Web of Science ®Google Scholar
• O’Sullivan CC. CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update. Expert Opin Pharmacother 2016;17:1657-67
   PubMed Web of Science ®Google Scholar
• Nakayama K, Nakayama K. Cip/Kip cyclin-dependent kinase inhibitors: brakes of the cell cycle engine during development. Bioessays 1998;20:1020-9
   PubMed Web of Science ®Google Scholar
• Landis MW, Pawlyk BS, Li T, et al. Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. Cancer Cell 2006;9:13-22
   PubMed Web of Science ®Google Scholar
• Choi YJ, Li X, Hydbring P, et al. The requirement for cyclin D function in tumor maintenance. Cancer Cell 2012;22:438-51
   PubMed Web of Science ®Google Scholar
• Buckley MF, Sweeney KJ, Hamilton JA, et al. Expression and amplification of cyclin genes in human breast cancer. Oncogene 1993;8:2127-33
   PubMed Web of Science ®Google Scholar
• An HX, Beckmann MW, Reifenberger G, et al. Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation. Am J Pathol 1999;154:113-18
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70
   PubMed Web of Science ®Google Scholar
• Rizzolio F, Tuccinardi T, Caligiuri I, et al. CDK inhibitors: from the bench to clinical trials. Curr Drug Targets 2010;11:279-90
   PubMed Web of Science ®Google Scholar
• Tan AR, Yang X, Berman A, et al. Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer. Clin Canc Res 2004;10:5038-47
   PubMed Web of Science ®Google Scholar
• Ramaswamy B, Phelps MA, Baiocchi R, et al. A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors. Investig New Drugs 2012;30:629-38
   PubMed Web of Science ®Google Scholar
• Sausville EA, Arbuck SG, Messmann R, et al. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol 2001;19:2319-33
   PubMed Web of Science ®Google Scholar
• O’Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4/6 inhibitors. Nature Rev Clin Oncol 2016;13:417-30
   PubMed Web of Science ®Google Scholar
• Benson C, White J, De Bono J, et al. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-roscovitine), administered twice daily for 7 days every 21 days. Br J Canc 2007;96:29-37
   PubMed Web of Science ®Google Scholar
• Herrera-Abreu MT, Palafox M, Asghar U, et al. Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancer. Canc Res 2016;76:2301-13
   PubMed Web of Science ®Google Scholar
• Lenihan C, Bouchekioua-Bouzaghou K, Shia A, et al. Abstract P3-06-02: Characterization of resistance to the selective CDK4/6 inhibitor palbociclib in ER positive breast cancer. Canc Res 2016;76(4Suppl):P3-06-02
   Web of Science ®Google Scholar
• Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Canc Ther 2004;3:1427-38
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Lorusso PM, Demichele A, et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Canc Res 2012;18:568-76
   PubMed Web of Science ®Google Scholar
• DeMichele A, Clark AS, Tan KS, et al. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb + advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. Clin Canc Res 2015;21:995-1001
   PubMed Web of Science ®Google Scholar
• Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomized phase 2 study. Lancet Oncol 2015;16:25-35
   PubMed Web of Science ®Google Scholar
• Finn RSCJ, Lang I, Boer K, et al. Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18). J Clin Oncol 2017;35(Suppl):abstr 1001
   Web of Science ®Google Scholar
• Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med 2016;375:1925-36
   PubMed Web of Science ®Google Scholar
• Finn R, Jiang Y, Rugo H, et al. Biomarker analyses from the phase 3 PALOMA-2 trial of palbociclib (P) with letrozole (L) compared with placebo (PLB) plus L in postmenopausal women with ER+/HER2- advanced breast cancer (ABC). Esmo Annual Meeting 2016:LBA15
   Google Scholar
• Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomized controlled trial. Lancet Oncol 2016;17:425-39
   PubMed Web of Science ®Google Scholar
• Arnedos M, Cheaib B, Bayar MA, et al. Anti-proliferative response and predictive biomarkers to palbociclib in early breast cancer: the Preoperative Palbociclib (POP) randomized trial. AACR Annual Meeting 2016:CT041
   Google Scholar
• Malorni LCG, Minisini AM, Cinieri S, et al. A phase II trial of the CDK4/6 inhibitor palbociclib (P) as single agent or in combination with the same endocrine therapy (ET) received prior to disease progression, in patients (pts) with hormone receptor positive (HR+) HER2 negative (HER2-) metastatic breast cancer (mBC) (TREnd trial). J Clin Oncol 2017;35(Suppl):abstr 1002
   Google Scholar
• A single arm phase II study of palbociclib in combination with tamoxifen as first line therapy for metastatic hormone receptor positive breast cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-016. ClinicalTrials.gov identifier: NCT02668666. Available at: www.clinicaltrials.gov [Last accessed 28 September 2016]
   Google Scholar
• PALbociclib CoLlaborative Adjuvant Study: a randomized phase III trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+)/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (PALLAS). ClinicalTrials.gov identifier: NCT02513394. Available at: www.clinicaltrials.gov [Last accessed 28 September 2016]
   Google Scholar
• A multicenter, randomized, double-blind phase 3 study of palbociclib (oral CDK 4/6 inhibitor) plus letrozole versus placebo plus letrozole for the treatment of previously untreated Asian postmenopausal women With ER (+), HER2 (-) advanced breast cancer (PALOMA-4). ClinicalTrials.gov identifier: NCT02297438. Available at: www.clinicaltrials.gov [Last accessed 28 September 2016]
   Google Scholar
• Phase III study evaluating palbociclib (PD-0332991), a cyclin-dependent kinase (CDK) 4/6 inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy (PENELOPEB). ClinicalTrials.gov identifier: NCT01864746. Available at: www.clinicaltrials.gov [Last accessed 28 September 2016]
   Google Scholar
• PATRICIA: A phase II clinical trial of combined palbociclib and trastuzumab, with or without letrozole, in post-menopausal patients with previously-treated locally advanced or metastatic HER2-positive breast cancer. ClinicalTrials.gov identifier: NCT02448420. Available at: www.clinicaltrials.gov [Last accessed 28 September 2016]
   Google Scholar
• Phase III study of palbociclib (PD-0332991) in combination with endocrine therapy (exemestane or fulvestrant) versus chemotherapy (capecitabine) in hormonal receptor (HR) positive/HER2 negative metastatic breast cancer (MBC) patients with resistance to non-steroidal aromatase inhibitors (PEARL). ClinicalTrials.gov identifier: NCT02028507. Available at: www.clinicaltrials.gov [Last accessed 28 September 2016]
   Google Scholar
• A phase II neoadjuvant study of palbociclib in combination with letrozole and trastuzumab as neoadjuvant treatment of stage II–III ER + HER2+ breast cancer (PALTAN). ClinicalTrials.gov identifier: NCT02907918. Available at: www.clinicaltrials.gov [Last accessed 28 September 2016]
   Google Scholar
• A randomized, multicenter, double-blind phase 3 study of PD-0332991 (oral CDK 4/6 inhibitor) plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER (+), HER2 (−) breast cancer who have not received any prior systemic anti cancer treatment for advanced disease (PALOMA-2). ClinicalTrials.gov identifier: NCT01740427. Available at: www.clinicaltrials.gov [Last accessed 28 September 2016]
   Google Scholar
• Gelbert LM, Cai S, Lin X, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Investig New Drugs 2014;32:825-37
   PubMed Web of Science ®Google Scholar
• Patnaik A, Rosen LS, Tolaney SM, et al. Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors. Canc Discovery 2016;6:740-53
   PubMed Web of Science ®Google Scholar
• Dickler MN, Tolaney SM, Rugo HS, et al. MONARCH1: results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease. J Clin Oncol 2016;34(Suppl):abstr 510
   Web of Science ®Google Scholar
• Tolaney SM, Beeram M, Beck JT, et al. A phase Ib study of abemaciclib with therapies for metastatic breast cancer. ASCO Meeting Abstracts 2015;33(15Suppl):abstr 522
   Google Scholar
• Hurvitz S, Abad M, Rostorfer R, et al. Interim results from neoMONARCH: a neoadjuvant phase II study of abemaciclib in postmenopausal women with HR +/HER2- breast cancer (BC). Paper presented at: European Society for Medical Oncology (ESMO) 2016 Congress, Copenhagen, Denmark, 7–11 October 2016
   Google Scholar
• Sledge GW Jr, Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol 2017: published online 3 June 2017. DOI: https://doi.org/10.1200/JCO.2017.73.7585
   Web of Science ®Google Scholar
• Lallena MJ, Boehnke K, Torres R, et al. Abstract 3101: in-vitro characterization of abemaciclib pharmacology in ER + breast cancer cell lines. Canc Res 2015;75(15Suppl):3101
   Web of Science ®Google Scholar
• A randomized, open-label, phase 2 study of abemaciclib plus tamoxifen or abemaciclib alone, in women with previously treated hormone receptor-positive, HER2-negative, metastatic breast cancer (nextMONARCH 1). ClinicalTrials.gov identifier: NCT02747004. Available at: www.clinicaltrials.gov [Last accessed 28 September 2016]
   Google Scholar
• MonarcHER: a phase 2, randomized, multicenter, 3-arm, open-label study to compare the efficacy of abemaciclib plus trastuzumab with or without fulvestrant to standard-of-care chemotherapy of physician’s choice plus trastuzumab in women with HR+, HER2+ locally advanced or metastatic breast cancer. ClinicalTrials.gov identifier: NCT02675231. Available at: www.clinicaltrials.gov [Last accessed 28 September 2016]
   Google Scholar
• A randomized, double-blind, placebo-controlled, phase 3 study to compare NSAI (anastrozole or letrozole) plus abemaciclib, a CDK4 and CDK6 inhibitor, or plus placebo, and to compare fulvestrant plus abemaciclib or plus placebo in postmenopausal women with hormone receptor-positive, HER2-negative locoregionally recurrent or metastatic breast cancer. ClinicalTrials.gov identifier: NCT02763566. Available at: www.clinicaltrials.gov [Last accessed 28 September 2016]
   Google Scholar
• A study of nonsteroidal aromatase inhibitors plus abemaciclib (LY2835219) in postmenopausal women with breast cancer (MONARCH 3). ClinicalTrials.gov identifier: NCT02246621. Available at: www.clinicaltrials.gov [Last accessed 28 September 2016]
   Google Scholar
• A study of abemaciclib (LY2835219) in participants with previously treated breast cancer that has spread (MONARCH 1). ClinicalTrials.gov identifier: NCT02102490. Available at: www.clinicaltrials.gov [Last accessed 28 September 2016]
   Google Scholar
• Infante JR, Shapiro G, Witteveen P, et al. A phase I study of the singleagent CDK4/6 inhibitor LEE011 in pts with advanced solid tumors and lymphomas. ASCO Meeting Abstracts 2014;32(15Suppl):abstr 2528
   Google Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 2016;375:1738-48
   PubMed Web of Science ®Google Scholar
• Bardia A, Modi S, Chavez-MacGregor M, et al. Phase Ib/II study of LEE011, everolimus, and exemestane in postmenopausal women with ER+/HER2-metastatic breast cancer. J Clin Oncol 2014;32(Suppl):abstr 535
   Web of Science ®Google Scholar
• Juric D, Ismail-Khan R, Campone M, et al. Abstract P3-14-01: phase Ib/II study of ribociclib and alpelisib and letrozole in ER+, HER2- breast cancer: safety, preliminary efficacy and molecular analysis. Canc Res 2016;76(4Suppl):P3-14-01
   Web of Science ®Google Scholar
• Juric D, Munster PN, Campone M, et al. Ribociclib (LEE011) and letrozole in estrogen receptor-positive (ER+), HER2-negative (HER2-) advanced breast cancer (aBC): phase Ib safety, preliminary efficacy and molecular analysis. 2016 ASCO Annual Meeting. J Clin Oncol 2016;34(Suppl):abstr 568
   Web of Science ®Google Scholar
• Goel S, Wang Q, Watt AC, et al. Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4/6 inhibitors. Cancer Cell 2016;29:255-69
   PubMed Web of Science ®Google Scholar
• Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer (MONALEESA-2) ClinicalTrials.gov identifier: NCT01958021. Available at: www.clinicaltrials.gov [Last accessed 28 September 2016]
   Google Scholar
• Study of efficacy and safety in premenopausal women with hormone receptor positive, HER2-negative advanced breast cancer (MONALEESA-7). ClinicalTrials.gov identifier: NCT02278120. Available at: www.clinicaltrials.gov [Last accessed 28 September 2016]
   Google Scholar
• Study of LEE011, BYL719 and letrozole in advanced ER + breast cancer. ClinicalTrials.gov identifier: NCT01872260. Available at: www.clinicaltrials.gov [Last accessed 28 September 2016]
   Google Scholar
• Phase Ib trial of LEE011 with everolimus (RAD001) and exemestane in the treatment of hormone receptor positive HER2 negative advanced breast cancer. ClinicalTrials.gov identifier: NCT01857193. Available at: www.clinicaltrials.gov [Last accessed 28 September 2016]
   Google Scholar
• Study of efficacy and safety of LEE011 in men and postmenopausal women with advanced breast cancer. (MONALEESA-3). ClinicalTrials.gov identifier: NCT02422615. Available at: www.clinicaltrials.gov [Last accessed 28 September 2016]
   Google Scholar
• Dillon RL, White DE, Muller WJ. The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene 2007;26:1338-45
   PubMed Web of Science ®Google Scholar
• Senderowicz AM, Sausville EA. Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst 2000;92:376-87
   PubMed Web of Science ®Google Scholar
• Liedtke C, Cardone L, Tordai A, et al. PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer. Breast Canc Res 2008;10:R27
   PubMed Web of Science ®Google Scholar
• Campbell IG, Russell SE, Choong DY, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004;64:7678-81
   PubMed Web of Science ®Google Scholar
• Perez-Tenorio G, Alkhori L, Olsson B, et al. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Canc Res 2007;13:3577-84
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam F, Esteva FJ. Potential role of mammalian target of rapamycin inhibitors in breast cancer therapy. Clin Breast Canc 2005;6:357-60
   PubMedGoogle Scholar
• DeGraffenried LA, Fulcher L, Friedrichs WE, et al. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann Oncol 2004;15:1510-16
   PubMed Web of Science ®Google Scholar
• Beeram M, Tan QT, Tekmal RR, et al. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol 2007;18:1323-8
   PubMed Web of Science ®Google Scholar
• Bachelot T, Bourgier C, Cropet C, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 2012;30:2718-24
   PubMed Web of Science ®Google Scholar
• Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520-9
   PubMed Web of Science ®Google Scholar
• Royce M, Villanueva C, Ozguroglu M, et al. BOLERO-4: phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor–positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC). Ann Oncol 2016;27:68-99
   PubMed Web of Science ®Google Scholar
• Robertson JF, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomized, double-blind, phase 3 trial. Lancet 2017;388:2997-3005
   Web of Science ®Google Scholar